In Depth 8 Jul 2024
Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR
Find out how the recent discovery of a molecular oddity found in bacteria has led to a new gene editing technique.
In Depth
- Latest Posts
In Depth 4 Jul 2024
Parkinson’s disease: biotech’s pursuit for more therapies
Rigorous research aims to boost therapeutic options for people with Parkinson’s disease. What do biotechs have in store?
In Depth 4 Jul 2024
The biggest private biotech investments in June 2024
The companies Formation Bio, Isotopen Technologien München, and Marea Therapeutics bagged the biggest private biotech investments in June 2024.
In Depth 1 Jul 2024
Special Olympics: How is biotechnology revolutionizing sports performance worldwide?
Find out about biotechnology’s impact on sports performance and recovery, from genetic profiling, stem cells, and wearable technologies.
In Depth 28 Jun 2024
Going nuclear: radiopharmaceuticals funding sees surge in 2024
Emerging as a new class of drugs, radiopharmaceuticals are all the rage in cancer treatment research as biotechs nab major funding deals.
In Depth 27 Jun 2024
CRISPR-Cas13: how does the technology compare to its famous Cas9 cousin?
Discover more about CRISPR-Cas13, including how it differs from CRISPR-Cas9 and what the technology can be used for.
ADVERTISEMENT
ADVERTISEMENT
In Depth 27 Jun 2024
The 2024 drug approval list: Eight new treatments you should know about
In this article, we take a look at eight much-anticipated drugs that have been approved by regulators so far this year.
In Depth 26 Jun 2024
Biotech megadeals: Exploring the surge in $100M+ deals
Biotech and healtcare contributed to more than one out of three megadeals in 2024, find out the reasons behind it.
In Depth 24 Jun 2024
Troublesome acquisitions: when biotech M&A goes wrong
Dive deeper into the world of M&A, as we take a look at some of the most prominent failed acquisitions of the last decade.
In Depth 19 Jun 2024
MASH candidates make a splash after first drug approval
The first drug to treat MASH, a potentially life-threatening liver disease, was approved this year. More recent advancements bring hope to patients.
In Depth 17 Jun 2024
Moving with the times: biopharma royalty deals on the rise
A spate of royalty deals are changing the way certain biotechs press ahead. This trend seems to be an alternative to traditional biopharma fundraising.
In Depth 12 Jun 2024
Stem cell therapy: a potential cure for hearing loss?
As stem cell research gains momentum, researchers are looking at ways to use the therapy to treat hearing loss.
ADVERTISEMENT
